hVIVO plc Result of Annual General Meeting (1331G)

TIDMHVO

RNS Number : 1331G

hVIVO plc

24 May 2017

For immediate release 2.00pm: 24 May 2017

HVIVO PLC

("hVIVO" or the "Company")

Result of Annual General Meeting

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 24 May 2017, were duly passed.

For further information please contact:

 
     hVIVO plc                                      [phone] 
     Kym Denny (Chief Executive Officer) 
     Graham Yeatman (Chief Financial & 
      Business Officer) 
 
     Numis Securities Limited                        [phone] 
     Michael Meade / Freddie Barnfield 
      (Nominated Adviser) 
     James Black / Michael Burke (Corporate 
      Broking) 
 
     FTI Consulting 
     Simon Conway / Victoria Foster Mitchell 
      (UK)                                          [phone] 
     John Capodanno / Evan Smith (US)               [phone] 
 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMUSSURBUAVUAR

(END) Dow Jones Newswires

May 24, 2017 09:00 ET (13:00 GMT)